Troluce Capital Advisors LLC Dyne Therapeutics, Inc. Transaction History
Troluce Capital Advisors LLC
- $1.91 Billion
- Q4 2024
A detailed history of Troluce Capital Advisors LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Troluce Capital Advisors LLC holds 50,000 shares of DYN stock, worth $695,500. This represents 0.21% of its overall portfolio holdings.
Number of Shares
50,000Holding current value
$695,500% of portfolio
0.21%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
211Shares Held
101MCall Options Held
150KPut Options Held
297K-
Atlas Venture Life Science Advisors, LLC8.02MShares$112 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$103 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$103 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$93.3 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$88.8 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $720M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...